BMC Ophthalmology · 2014 · 35 citations · 18 references
MedicineNeurologyOphthalmologyNeuro-ophthalmologyOcular DiseaseVisual DisordersNeuro-optometric AssessmentVisual Field AssessmentVisual Field DefectsVisual ImpairmentVisual Loss EvaluationControl Group DesignIntravenous Corticosteroid TherapyMatched Control GroupNonarteritic Anterior Ischemic Optic NeuropathyOptic Nerve-related Visual Field DefectsStatic Visual AcuityTherapeutic CorticosteroidsVisual Field Perimetry
BACKGROUND: To date, non arteritic anterior ischemic optic neuropathy (NAION) is still incurable. We wish to evaluate the effect of intravenous (IV) corticosteroids on the visual outcome of NAION patients. METHODS: Visual parameters were retrospectively compared between NAION patients treated with IV corticosteroids and untreated NAION patients (control). Visual acuity (VA) and Humphrey automated static perimetry visual field (VF) defects of the affected eye were compared between groups at baseline, 1, 3, 6 months, and end of follow-up visits. The VF analysis consisted of number of quadrant involvements and mean deviation (MD). RESULTS: Each group comprised 23 patients (24 eyes). Mean initial VA was similar in the control and treatment groups (p = 0.8). VA at end of follow-up did not improve in either groups (p = 0.8 treated group, p = 0.1 control group). No improvement and no difference in VF defects were found by either quadrant analysis (p = 0.1 treated group, p = 0.5 control group) or MD analysis (p = 0.2, treated group, p = 0.9 control group). VA and VF parameters tended to be worse in the treated group, although without statistical significance. CONCLUSIONS: Our results suggest that IV corticosteroids may not improve the visual outcome of NAION patients. Since intravenous corticosteroids could potentially cause serious adverse effects, this treatment for NAION is questionable.
18